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a b s t r a c t
Animal and emerging clinical studies have demonstrated that increased ventricular ﬁbrosis in a setting of
reduced repolarization reserve promotes early afterdepolarizations (EADs) and triggered activity that can
initiate ventricular tachycardia and ventricular ﬁbrillation (VT/VF). Increased ventricular ﬁbrosis plays a
key facilitatory role in allowing oxidative and metabolic stress-induced EADs to manifest as triggered
activity causing VT/VF. The lack of such an arrhythmogenic effect by the same stressors in normal non-
ﬁbrotic hearts highlights the importance of ﬁbrosis in the initiation of VT/VF. These ﬁndings suggest that
antiﬁbrotic therapy combined with therapy designed to increase ventricular repolarization reserve may
act synergistically to reduce the risk of sudden cardiac death.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Classically, increased cardiac ﬁbrosis has been shown to be
associated with altered cardiac conduction, causing conduction
slowing, block, and reentry in studies on isolated animal and
diseased human cardiac tissues [1–3]. Interestingly, similar ﬁndings
were also demonstrated in isolated Langendorff-perfused explanted
human hearts with dilated cardiomyopathy [4,5]. While alterations
of cardiac conduction [6,7] and the resulting reentrant wavefront of
excitation [8] are uniformly accepted as arrhythmic consequences of
increased cardiac ﬁbrosis, recent experimental and computational
studies indicate that ﬁbrosis may also importantly modulate the
formation of cardiac afterpotentials, notably early afterdepolariza-
tions (EADs), that lead to triggered activity causing atrial ﬁbrillation
(AF) [9] and ventricular ﬁbrillation (VF) [10–12]. Taken together,
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these ﬁndings indicate that increased cardiac ﬁbrosis promotes
tachyarrhythmias not only by the mechanism of reentry but also by
the mechanism of triggered activity, potentially making cardiac
ﬁbrosis a highly effective antiarrhythmic target.
In this review, we demonstrate how the interaction of ﬁbrotic
ventricles with oxidative or metabolic stress leads to the emergence
of EADs, triggered activity, and VF. Speciﬁcally, we describe the
dynamic scenario starting from cellular EADs that promote trig-
gered activity causing focal ventricular tachycardia (VT), which then
degenerates to VF. We also discuss recent experimental and clinical
studies that show the potential antiarrhythmic beneﬁts of drug-
induced prevention and/or reduction of ventricular ﬁbrosis [13–17].
1.1. The pathology of ﬁbrosis
Cardiac ﬁbrosis develops when the body's natural wound-
healing process becomes altered, causing abnormally elevated
ﬁbrosis by mechanisms that still remain poorly deﬁned. Under
normal (adaptive) conditions of wound healing, specialized cells
known as ﬁbroblasts become activated and transform into myoﬁ-
broblasts. The myoﬁbroblasts then undergo proliferation, causing
increased synthesis of collagen protein in the extracellular matrix
composed predominantly of type I collagen and to a lesser extent
type III collagen (normal wound healing process). What is initially
an adaptive process, perhaps meant to enhance tensile strength,
can progress to maladaptive (pathologic) conditions when the
“healing” process persists with the development of excessive
myocardial ﬁbrosis [15,18–20]. While resident cardiac ﬁbroblasts
may be activated and transformed into myoﬁbroblasts, there is
also the potential of participation by ﬁbroblasts originating from
either endothelial cells via endothelial–mesenchymal transition
(EndMT) or from the bone marrow [21,22] and the spleen [23].
For example, it has been shown that transforming growth factor-
beta 1 (TGF-β1) induces endothelial cells to undergo EndMT,
whereas bone morphogenic protein 7 (BMP-7) preserves the
endothelial phenotype. The demonstration that the systemic
administration of recombinant human BMP-7 (rhBMP-7) signiﬁ-
cantly inhibits EndMT and the progression of cardiac ﬁbrosis in
mouse models of pressure overload provides new insights into the
progression of pathological (maladaptive) cardiac ﬁbrosis [24].
1.2. Aged heart animal model of ﬁbrosis
Atrial and ventricular ﬁbrosis may indeed increase with aging,
but ﬁbrosis per se does not promote cardiac arrhythmia [25–28].
Instead, ﬁbrosis provides a substrate that when coupled to a mild
form of stress (oxidative or metabolic), which is of no arrhythmic
consequence in non-ﬁbrotic hearts, promotes EADs and triggered
activity causing VT and VF in ﬁbrotic hearts, as shown in Fig. 1. We
describe the key role played by increased ventricular ﬁbrosis using
the aged rat model exposed to either oxidative stress caused by
either hydrogen peroxide (H2O2) [10] or glycolytic inhibition (GI)
induced by replacing glucose with pyruvate [12]. This substitution
deprives the sarcoplasmic reticulum (SR) of high-energy phos-
phate (ATP) needed for proper reuptake of intracellular calcium
from the cytoplasm [29,30].
2. Oxidative stress
Hydrogen peroxide (H2O2) is shown to readily promote EADs
and triggered activity in isolated rat and rabbit ventricular myo-
cytes by increasing both the L-type Ca channel (ICa-L) and late
sodium currents (INa-L) [31–35]. However, this same stress fails to
cause EADs in normal non-ﬁbrotic cardiac tissue [10,12]. The
discrepancy between non-ﬁbrotic and ﬁbrotic heart tissues in
Fig. 1. Simultaneous microelectrode and ECG recordings at the onset of VT/VF in an aged rat heart exposed to 0.1 mM H2O2. Panel A, onset of early afterdepolarization (EAD)-
mediated triggered activity (TA) causing ventricular tachycardia (VT) 5 min after H2O2 exposure. Note the smooth emergence of EAD (upward-pointing arrow) during the
isoelectric interval on the ECG followed by a run of 10 TA (downward-pointing arrow) causing non-sustained VT on the ECG. The onset of the EAD precedes the QRS complex
of the VT by 8 ms, indicating absence of electrical activity elsewhere in the heart. Two additional short runs of VT with 4 beats each are also shown that follow a single
subthreshold EAD (downward-pointing small arrow) with no TA. Panel B shows the degeneration of the TA to VF 15 min after H2O2 exposure. (From Ref. [10].)
N. Morita et al. / Journal of Arrhythmia 30 (2014) 389–394390
the genesis of EAD-mediated triggered activity either in isolated
single myocytes or at the tissue level may result from the “source-
to-sink” mismatch [36]. This phenomenon occurs as follows: at a
ventricular site, some cells that become greatly stressed and
generate EADs (i.e., “source”) may be electrically well coupled to
adjoining cells that do not generate EADs and instead repolarize
normally back to the resting potential. In this case, such adjoining
cells exert a repolarizing inﬂuence on the cells that are prone to
generate EADs, i.e., “sink effect,” thus suppressing the EADs. Stated
otherwise, EAD as the source becomes incapable of overriding the
repolarizing sink effect exerted by the electrically coupled nor-
mally repolarizing cells, which results in EAD suppression. The
importance of the diffusive electrotonic cellular coupling on the
modulation of EADs was systematically studied using simulation.
For example, when 2 isolated ventricular myocytes were artiﬁ-
cially well coupled via a variable electrical resistor, with 1 cell
generating EADs and the other cell devoid of EADs, EADs in the
ﬁrst cell were suppressed if the second cell had normal repolar-
ization. However, if the same cell with EADs was uncoupled from
the cell with normal repolarization by applying an inﬁnite elec-
trical resistance between the 2 cells (i.e., complete cellular uncou-
pling, mimicking an isolated single myocyte) the EADs emerged
again [37,38]. These single-cell studies were later expanded in a
thorough systematic study using 1-, 2-, and 3-dimensionally
arranged (1D, 2D, and 3D) tissues to determine the number of
contiguous cells with EADs required to override the sink effect and
allow the EAD-mediated triggered beats to propagate to the
surrounding tissue. For example, using a realistic cardiac cell
model, it was shown that in 3D normally-coupled tissue, one
needs approximately 700,000 contiguous cells to synchronously
produce EADs in order to overcome the source-to-sink mismatch
and allow a triggered premature ventricular contraction (PVC) to
propagate [36]. In 2D tissue, this number decreases to approxi-
mately 7000, and in a 1D cable to approximately 70. Interestingly,
and as expected, the minimum number of cells needed to produce
a propagated EAD-induced PVC in 3D tissue decreased by as much
as 40-fold when cell-to-cell gap junctional coupling is reduced
[36]. Fibrosis, which imposes insulating collagen bands between
strands of myocytes (essentially converting 3D tissue into a net-
work of 1D cables), is even more potent at reducing the number of
myocytes required for PVC formation [36]. These experimental and
simulation studies strongly suggest that the observed discrepancy
in EAD production between isolated myocytes and normally
coupled cardiac tissue may indeed result from the source-to-sink
mismatch. In well-coupled cardiac tissue, the source-to-sink
mismatch provides a powerful protective effect for suppression
of EAD formation by delinquent cells, preventing the emergence of
cardiac arrhythmias. Fig. 2 describes schematically the relation-
ships between ﬁbrosis and repolarization reserve reduction under
3 different conditions: the isolated single myocyte, normal tissue,
and ﬁbrotic tissue. Based on the ﬁndings above, it could be
surmised that cardiac diseases that cause myocyte decoupling
should facilitate the emergence of EADs when the repolarization
reserve is reduced. A number of factors reduce cellular coupling in
diseased heart, including gap junction remodeling and ﬁbrosis.
Fibrosis forms insulating barriers between cells and groups of cells
through the interstitial tissue deposit of collagenous ﬁlaments by
the proliferating cardiac myoﬁbroblasts [19,20]. We have shown
that aging in rats and rabbits manifests not only increased cardiac
ﬁbrosis but also down-regulation of the gap junctional connex-
ins43 (Cx43) [12,39] that effectively reduce the coupling conduc-
tance between cardiac myocytes.
3. Metabolic stress
Glycolysis accounts for less than 5% of total cellular ATP produc-
tion in the beating heart under aerobic conditions. However, studies
of isolated cardiac myocytes have shown that cardiac stress induced
by selectively inhibiting glycolytic ATP production can lead to
electromechanical alternans and triggered action potentials, without
affecting mitochondrial ATP production or redox state [30,40]. We
have shown that ﬁbrotic aged hearts but not non-ﬁbrotic adult hearts
are highly vulnerable to EAD-mediated triggered activity causing
VT/VF during GI. With GI, simultaneous shortening of the action
potential duration (APD) and slowing of intracellular calcium
ð½Cai2þ Þ decline rate results in elevation of ½Cai2þ  during phase
3 repolarization, a condition shown to promote EADs in ﬁbrotic
rabbit ventricles [41] and in canine pulmonary veins [42] and atria
[43]. Maintained elevation of ½Cai2þ  enhances the forward mode of
the Naþ/Ca2þ exchanger (NCX), generating a net depolarizing
inward current [42,44]. Inhibition of the NCX prevents GI-mediated
EADs, which supports this scenario [12].
3.1. From EADs to focal VT in intact hearts
To gain insight into the cellular mechanisms of focal VT, we
performed high-resolution optical mapping of the left ventricular
(LV) epicardial surface during GI or oxidative stress. Consistent with
the theory of source-to-sink mismatch, the focal VT at the onset of VF
originated from the LV region with an intermediate degree (“critical
degree”) of ﬁbrosis that was located at the base of the left ventricle.
We performed continuous recording of single cell action potentials
with a glass microelectrode from the epicardial surface of the LV
base, where the focal VT frequently originated. This showed that the
focal VT was initiated by an EAD-mediated triggered activity that
arose from a mean take-off potential of 51716 mV (Fig. 1). The
mean cycle length(CL) of the triggered activity was 66710 ms and
was not signiﬁcantly different from the mean CL of the VT
(70718 ms). The EAD preceded the QRS complex of a simulta-
neously recorded ECG by a mean of 874 ms and occurred during an
isoelectric interval of the ECG. This indicated absence of electrical
activity elsewhere in the heart during the EAD formation. The EADs
arose when ½Cai2þ  remained high relative to the diastolic level,
activating the NCX, which then provided a net inward depolarizing
current promoting EADs [12].
3.2. Transition from focal VT to VF
The EAD-mediated focal VT degenerates within 3 s of the VT
onset into sustained VF. The focal VT initially propagated as single
Fig. 2. Schematic drawing of the relationship between increased ﬁbrosis and
reduced repolarization reserve in the initiation of EADs under 3 different condi-
tions. Notice that a similar level of stress (0.1 mM H2O2) promotes EADs only at the
isolated single cell level and in ﬁbrotic hearts but not in normal hearts.
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wavefront from the base of the heart. This promoted spatially
discordant APD alternans, causing wavebreak and leading to
reentry and subsequent disorganization of the wavefront to multi-
ple irregular wavelets that signal the onset of VF [12]. This
dynamic scenario is shown in Fig. 3.
4. Do myocardial cells in the aged heart undergo electrical
remodeling?
Although disruption of normal cell-to-cell coupling by ﬁbrosis
provides a plausible explanation for the increased susceptibility of
aged hearts to EADs and EAD-mediated arrhythmias, there remains
the possibility that aged ventricular myocytes, unlike adult myocytes,
become exquisitely sensitive to stress-mediated EADs and triggered
activity. To test whether this happens, we studied aged and adult
isolated myocytes under patch-clamp conditions and subjected them
to similar degrees of stresses. No difference was found between the
aged and adult isolated myocytes in their abilities to generate EADs
[45]. This indicates lack of electrical remodeling at the single-cell
level, making a strong case for enhanced ﬁbrosis in the genesis of
EAD at the whole-heart level.
5. The role of anti-ﬁbrotic therapy against VT/VF
The link between ventricular ﬁbrosis and the risk of ventricular
arrhythmia in the setting of reduced repolarization reserve sug-
gests that targeting both ﬁbrosis and reversal of stress-induced
repolarization reserve reduction may be important strategies to
prevent VT/VF. We recently have shown that increase in the
repolarization reserve by blocking late inward Naþ current with
ranolazine suppressed and prevented oxidative stress-induced
EADs, triggered activity, and VT/VF in aged ﬁbrotic rat hearts
[11]. This pharmacological strategy to suppress EAD-mediated VF
appears very promising, as it does not interfere with the normal
physiological cardiac ion channel function but instead normalizes
the delayed inactivation of the Na current (late INa) while preser-
ving normal excitation–contraction coupling [11]. In addition to
increasing the repolarization reserve, new antiﬁbrotic strategies
are being developed that hold promise for future effective pre-
vention of sudden cardiac death caused by VF. For example, a
recent study found that in patients with hypertrophic cardiomyo-
pathy, myocardial ﬁbrosis as measured by late gadolinium
enhancement cardiovascular magnetic resonance (CMR) was an
independent predictor of adverse outcome [46]. Interestingly,
these investigators found that the extent of myocardial ﬁbrosis
was an independent predictor for arrhythmias including sustained
VT and VF [46].
In another study Lopez and associates found that patients with
chronic heart failure receiving torsemide, a loop diuretic that
inhibits the enzyme involved in the myocardial extracellular
generation of collagen type I molecules (i.e., procollagen type I
carboxy-terminal proteinase or PCP), had reduced myocardial
collagen volume fraction (CVF) as assessed in right septal endo-
cardial biopsies [47]. Interestingly, changes in serum PCP activa-
tion were positively correlated with changes in CVF in the patients
receiving torsemide [47]. These initial clinical studies suggest that
Fig. 3. Spontaneous initiation of VT/VF in an aged rat heart exposed to 0.1 mM H2O2. Panel A is an ECG showing the last 4 sinus beats before the sudden onset of VT leading
to VF. Panel B shows voltage snapshots of the last beat of the VT (beat #1) and of the ﬁrst 2 beats of the VF (beats #2 & #3). In each snapshot, activation time in milliseconds
is shown at the bottom right with time 0 (arbitrary) coinciding with the onset of beat #1. The red color in the snap shots represents depolarization (DEP) and the blue
repolarization (REP) as shown in panel C. The yellow arrows in the snap shots represent the direction of the wavefront propagation with double horizontal lines denoting the
site of conduction block. The VT originates from a focal site at the LV base and propagates as a single wavefront towards the apex and undergoes functional conduction block
at site 3. The 2 lateral edges of the front, however, continue to propagate laterally (snap shot 98 ms) forming ﬁgure-8 reentry (snapshot 108 ms). During the second reentrant
wavefront another wavefront emerges from the apical site of the LV (snapshot 122 ms), disrupting the activation pattern and signaling the onset of VF. Panel D shows
3 optical action potentials (labeled 1, 2, and 3) recorded from sites identiﬁed on the heart silhouette (Panel E). The 2 downward-pointing blue arrows indicate the direction of
propagation from site 1 to site 3 with the red downward-pointing arrow showing block at site 3 followed by retrograde activation (upward-pointing arrow). Notice the
emergence of spatially discordant action potential duration (APD) alternans preceding conduction block at site 3 when the front with short APD (S) at site 1 encroaches at a
site (site 3) with long APD (L). S indicates short and L long APD. (From Ref. [10].)
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ventricular ﬁbrosis may indeed be decreased using antiﬁbrotic
therapy; however, its antiarrhythmic signiﬁcance awaits conﬁrma-
tion in larger patient populations. The emergence of new cardiac
imaging techniques for myocardial ﬁbrosis with reasonable
degrees of accuracy [48] may help assess the efﬁcacy of antiﬁbrotic
therapy for the associated cardiac arrhythmias. Antiarrhythmic
therapy would thus be targeted to prevent disproportionate
collagen accumulation and myoﬁbroblast proliferation. Such mea-
sures will not only prevent arrhythmias, but also help in the
management of heart failure. Collectively, there are a wide range
of possible preventive antiﬁbrotic treatment options that target
TGF-β, endothelin-1 (ET-1), connective tissue growth factor
(CTGF), angiotensin II, and platelet-derived growth factor (PDGF)
networks [15]. The experimental ﬁndings are encouraging, and
suggest that reduction of cardiac ﬁbrosis is possible and may
indeed reduce the risk of cardiac arrhythmias. For example, studies
in rats have shown that pirfenidone mitigates left ventricular
ﬁbrosis and dysfunction after myocardial infarction and reduces
arrhythmias [49,50] Another animal study showed that the agent
relaxin-1 reverses cardiac ﬁbrosis and related cardiac dysfunction
[51]. Relaxin is a potent antiﬁbrotic peptide hormone that inhibits
ﬁbroblast activation (indicated by suppressed expression of α-
smooth muscle actin) and collagen synthesis stimulated by angio-
tensin II or TGF-β [51].
6. Conclusions
It is hoped that these basic research ﬁndings will be translated into
treatments for patients at risk for developing cardiac ﬁbrosis-related
arrhythmias. To the extent that such a translation will be successful, it
is anticipated that a more rational and effective management of
patients at risk for VT/VF may be developed. Sudden cardiac death
prematurely claims some 300,000 lives each year in the US and
50,000–100,000 lives in Japan, and it remains a global public health
problem. New treatment modalities such as reduction of cardiac
ﬁbrosis and reversal of repolarization reserve reduction without
interfering with excitation-contraction coupling hold future promise.
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